Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18985917 | 0.86 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL25551409 | 0.84 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL3341045 | 0.80 | NR3C2 (0.50) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL13036111 | 0.79 | NISCH (0.47) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL27975555 | 0.79 | BRD4 (0.50) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL18518468 | 0.79 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL20439019 | 0.78 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL12492615 | 0.78 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL1226389 | 0.78 | P2RX7 (0.41) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL24497540 | 0.77 | KDM5A (0.52) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-23 | — | — | US | disclosed |
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-25 | — | — | US | disclosed |
| WO-2017125530-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-27 | — | — | WO | disclosed |
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX6, P2RX3 | PIK3CD 3158/4885PIK3CA 1866/4885PIK3CB 3229/4885 |
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | PIK3CD 479/4885PIK3CA 661/4885PIK3CB 379/4885 |
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | NFKBIA, MAP3K14, IKBKG | PIK3CD 407/4885PIK3CA 657/4885PIK3CB 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.